Neil Kumar

Dr. Kumar, Ph.D., is a co-founder and has served as Chief Executive Officer and a member of the board of directors at BridgeBio since April 2015. Dr. Kumar has also served as the Chief Executive Officer of Eidos Therapeutics, Inc. (Nasdaq: EIDX), a clinical stage biopharmaceutical company, and a member of Eidos Therapeutics’ board of directors since March 2016. Prior to that, he served as the interim vice president of business development at MyoKardia, Inc. (Nasdaq: MYOK). Prior to that, Dr. Kumar was a principal at Third Rock Ventures and an associate principal at McKinsey & Company.